View in EDS

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.

Saved in:
Bibliographic Details
Title: Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
Authors: Goyal L; Department of Medicine, Stanford University School of Medicine, & the Stanford Cancer Center, Palo Alto, CA, USA., Meric-Bernstam F; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hollebecque A; Drug Development Department, Gustave Roussy, Villejuif, France., Valle JW; Cholangiocarcinoma Foundation, Herriman, UT, USA.; Division of Cancer Sciences, University of Manchester, Manchester, UK., Morizane C; National Cancer Center Hospital, Tokyo, Japan., Karasic TB; Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Abrams TA; Mass General Cancer Center, Harvard Medical School, & Dana-Farber Cancer Institute, Boston, MA, USA., Furuse J; Kanagawa Cancer Center, Yokohama, Japan., Kelley RK; University of California, San Francisco, San Francisco, CA, USA., Cassier PA; Centre Léon Bérard, Lyon, France., Klümpen HJ; Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Chang HM; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Chen LT; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan., Tabernero J; Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, University of Vic-Central University of Catalonia, Baselga Oncologic Institute, Hospital Quiron, Barcelona, Spain., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Mahipal A; Mayo Clinic, Rochester, MN, USA., Moehler M; University Medical Center of Johannes Gutenberg University, Mainz, Germany., Komatsu Y; Hokkaido University Hospital Cancer Center, Sapporo, Japan., Ahn DH; Mayo Clinic, Phoenix, AZ, USA., Epstein RS; Epstein Health, Woodcliff Lake, NJ, USA., Halim AB; Taiho Oncology, Inc., Princeton, NJ, USA., Wacheck V; Taiho Oncology, Inc., Princeton, NJ, USA., He Y; Taiho Oncology, Inc., Princeton, NJ, USA., Liu M; Taiho Oncology, Inc., Princeton, NJ, USA., Benhadji KA; Taiho Oncology, Inc., Princeton, NJ, USA., Bridgewater JA; University College London Cancer Institute, London, UK.
Corporate Authors: FOENIX-CCA2 Study Investigators
Source: Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (36), pp. 2811-2822. Date of Electronic Publication: 2024 Jun 17.
Publication Type: Patient Education Handout
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38884254
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Goyal+L%22">Goyal L</searchLink>; Department of Medicine, Stanford University School of Medicine, & the Stanford Cancer Center, Palo Alto, CA, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hollebecque+A%22">Hollebecque A</searchLink>; Drug Development Department, Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Valle+JW%22">Valle JW</searchLink>; Cholangiocarcinoma Foundation, Herriman, UT, USA.; Division of Cancer Sciences, University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Morizane+C%22">Morizane C</searchLink>; National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Karasic+TB%22">Karasic TB</searchLink>; Hospital of the University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Abrams+TA%22">Abrams TA</searchLink>; Mass General Cancer Center, Harvard Medical School, & Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Furuse+J%22">Furuse J</searchLink>; Kanagawa Cancer Center, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Kelley+RK%22">Kelley RK</searchLink>; University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cassier+PA%22">Cassier PA</searchLink>; Centre Léon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Klümpen+HJ%22">Klümpen HJ</searchLink>; Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Chang+HM%22">Chang HM</searchLink>; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Chen+LT%22">Chen LT</searchLink>; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Tabernero+J%22">Tabernero J</searchLink>; Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, University of Vic-Central University of Catalonia, Baselga Oncologic Institute, Hospital Quiron, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Mahipal+A%22">Mahipal A</searchLink>; Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Moehler+M%22">Moehler M</searchLink>; University Medical Center of Johannes Gutenberg University, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Komatsu+Y%22">Komatsu Y</searchLink>; Hokkaido University Hospital Cancer Center, Sapporo, Japan.<br /><searchLink fieldCode="AU" term="%22Ahn+DH%22">Ahn DH</searchLink>; Mayo Clinic, Phoenix, AZ, USA.<br /><searchLink fieldCode="AU" term="%22Epstein+RS%22">Epstein RS</searchLink>; Epstein Health, Woodcliff Lake, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Halim+AB%22">Halim AB</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Wacheck+V%22">Wacheck V</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22He+Y%22">He Y</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Liu+M%22">Liu M</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Benhadji+KA%22">Benhadji KA</searchLink>; Taiho Oncology, Inc., Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Bridgewater+JA%22">Bridgewater JA</searchLink>; University College London Cancer Institute, London, UK.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22FOENIX-CCA2+Study+Investigators%22">FOENIX-CCA2 Study Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2024; Vol. 20 (36), pp. 2811-2822. <i>Date of Electronic Publication: </i>2024 Jun 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Patient Education Handout
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38884254
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2024.2364504
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2811
    Titles:
      – TitleFull: Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Goyal L
      – PersonEntity:
          Name:
            NameFull: Meric-Bernstam F
      – PersonEntity:
          Name:
            NameFull: Hollebecque A
      – PersonEntity:
          Name:
            NameFull: Valle JW
      – PersonEntity:
          Name:
            NameFull: Morizane C
      – PersonEntity:
          Name:
            NameFull: Karasic TB
      – PersonEntity:
          Name:
            NameFull: Abrams TA
      – PersonEntity:
          Name:
            NameFull: Furuse J
      – PersonEntity:
          Name:
            NameFull: Kelley RK
      – PersonEntity:
          Name:
            NameFull: Cassier PA
      – PersonEntity:
          Name:
            NameFull: Klümpen HJ
      – PersonEntity:
          Name:
            NameFull: Chang HM
      – PersonEntity:
          Name:
            NameFull: Chen LT
      – PersonEntity:
          Name:
            NameFull: Tabernero J
      – PersonEntity:
          Name:
            NameFull: Oh DY
      – PersonEntity:
          Name:
            NameFull: Mahipal A
      – PersonEntity:
          Name:
            NameFull: Moehler M
      – PersonEntity:
          Name:
            NameFull: Komatsu Y
      – PersonEntity:
          Name:
            NameFull: Ahn DH
      – PersonEntity:
          Name:
            NameFull: Epstein RS
      – PersonEntity:
          Name:
            NameFull: Halim AB
      – PersonEntity:
          Name:
            NameFull: Wacheck V
      – PersonEntity:
          Name:
            NameFull: He Y
      – PersonEntity:
          Name:
            NameFull: Liu M
      – PersonEntity:
          Name:
            NameFull: Benhadji KA
      – PersonEntity:
          Name:
            NameFull: Bridgewater JA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 36
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1